Antonoglou Georgios N, Sándor George K
Institute of Dentistry, Department of Periodontology and Geriatric Dentistry, University of Oulu, Finland.
Department of Oral and Maxillofacial Surgery, Oulu University Hospital, University of Oulu and Director of Research, BioMedoTech, Institute of Biosciences and Medical Technology, University of Tampere, Finland.
J Craniomaxillofac Surg. 2015 Jan;43(1):149-57. doi: 10.1016/j.jcms.2014.10.027. Epub 2014 Oct 31.
The aim of the present study was to define and evaluate the post-treatment recurrence of unicystic and solid or multicystic ameloblastoma lesions, measured as counts of first time recurrences.
A systematic review of the literature and meta-analysis was planned according to the PRISMA statement and in order to include randomized and non-randomized clinical trials and observational studies in humans. Seven electronic databases were searched from their start up to December 2013 without limitation to year, language or publication status.
A total of seven non-randomized studies with 229 cases of treated ameloblastoma lesions were included in the quantitative synthesis. The summary recurrence rate of ameloblastomas for the unicystic and solid or multicystic variants ranged from 0.2% to 12% and 0.8% to 38% respectively. The comparison of a conservative treatment approach versus radical in solid or multicystic ameloblastoma favored the radical.
The absence of studies with low risk of bias precludes the making of strong clinical recommendations while resection may be preferable in both unicystic and solid or multicystic. ameloblastomas.
本研究的目的是定义并评估单囊型和成实性或多囊型成釉细胞瘤病变的治疗后复发情况,以首次复发计数来衡量。
根据PRISMA声明计划进行文献系统评价和荟萃分析,以便纳入针对人类的随机和非随机临床试验及观察性研究。检索了七个电子数据库,从其建立到2013年12月,不限年份、语言或出版状态。
定量综合分析共纳入七项非随机研究,涉及229例接受治疗的成釉细胞瘤病变。单囊型和成实性或多囊型成釉细胞瘤的汇总复发率分别为0.2%至12%和0.8%至38%。在实性或多囊型成釉细胞瘤中,保守治疗方法与根治性治疗方法的比较结果支持根治性治疗。
由于缺乏偏倚风险低的研究,无法提出强有力的临床建议,而对于单囊型和成实性或多囊型成釉细胞瘤,手术切除可能是更可取的。